Ordering
Available Variants10 mg
CHA.43814-10mg
Price
€164.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.43814-10mg | €164.00 |
phyproof® Reference Substance
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C15H18N2O |
|---|---|
| CAS Number | 102518-79-6 |
| Molecular Weight | 242.32 |
| UNSPSC Code | 41116107 |
| NACRES | NA.24 |
| MDL number | MFCD01714949 |
Safety Information Handling visibility
| pictograms |
GHS06
 GHS06
|
|---|---|
| signalword | Danger |
| hcodes | H300 + H310 + H330 |
| pcodes | P260 - P262 - P264 - P280 - P302 + P352 + P310 - P304 + P340 + P310 |
| Hazard Classifications | Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral |
| Storage Class | 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Huperzine A, with the chemical identifier CAS: 102518-79-6, is a naturally occurring sesquiterpene alkaloid compound that has garnered significant attention in the scientific community due to its potential pharmacological properties. Isolated from the Chinese club moss Huperzia serrata, this compound has been found to exhibit a range of biological activities, including neuroprotective and acetylcholinesterase inhibitory effects. Research has suggested that Huperzine A may have therapeutic potential in the treatment of various neurological disorders, including Alzheimers disease and other cognitive impairments. Further studies are necessary to fully elucidate the mechanisms of action and potential clinical applications of Huperzine A, but its unique structure and bioactivity profile make it an intriguing candidate for continued investigation in the fields of neuroscience and pharmacology. Its potential benefits and limitations are being explored in ongoing scientific research.
